Krónikus limfoid leukémia (CLL): vizsgálatok itt: Egyesült Királyság
33 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Where
- London-Camden, Nottingham
- Életkor
- 18 év and over
- People
- 735 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05947851 · EU 2022-501560-17-00 - 1. fázisTaking peopleA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Where
- Manchester, Oxford
- Életkor
- 18 év and over
- People
- 332 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05091424 - 2. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Birmingham, Glasgow, Harrow, Leeds, Lincoln, Liverpool, London, Swansea
- Életkor
- 18 év and over
- People
- 249 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT06588478 · EU 2024-515689-15-01 - 1. fázisCsak meghívásosA Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
- Where
- Leicester, London, Plymouth
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00 - 4. fázisTaking peopleA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Hull, Leeds, Newmarket
- Életkor
- 18 év and over
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07218341 - 2. fázisTaking peopleA Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Where
- Headington, London, Manchester
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- Nurix Therapeutics, Inc.
See details and how to joinNCT07221500 - 1/2. fázisTaking peopleA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Where
- Derriford, London, Oxford, Southampton
- Életkor
- 18 év and over
- People
- 408 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06564038 · EU 2024-515034-33-00 - 2. fázisTaking peopleEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Where
- Bristol, London, Manchester, Newmarket, Nottingham, Oxford, Sutton, Windsor
- Életkor
- 18 év and over
- People
- 490 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00 - 1/2. fázisTaking peopleA Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Where
- Birmingham, Leeds
- Életkor
- 18 év and over
- People
- 258 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06697184 · EU 2024-518829-15-00 - 3. fázisTaking peopleA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Where
- Bournemouth, Headington, Leeds, London, Metropolitan Borough of Wirral, Newcastle upon Tyne, Truro
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00 - 2. fázisTaking peopleMAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
- Where
- Colchester, Derby, Edgbaston, Exeter, Leeds, London, Southampton
- Életkor
- 18 év to 130 év
- People
- 80 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07024706 · EU 2024-518858-17-00 - 3. fázisTaking peopleSingle-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Where
- Leicester, London
- Életkor
- 18 év and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00 - 3. fázisTaking peopleA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Where
- Barnet, Bristol, Lancaster, Leeds, London, Newmarket, Nottingham, Oxford, Windsor
- Életkor
- 18 év and over
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136559 · EU 2022-501697-19-01 - 1/2. fázisTaking peopleSafety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
- Where
- Glasgow, Liverpool, Sutton
- Életkor
- 1 év to 17 év
- People
- 70 worldwide
- Run by
- Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00 - 3. fázisTaking peopleSurovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Where
- Edinburgh, Hampshire, Leeds, London, Manchester, Nottingham, Oxford, Sutton
- Életkor
- 18 év to 18 év
- People
- 420 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07509151 - 1/2. fázisTaking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Edinburgh, Leeds, Newcastle upon Tyne, Newmarket, Norwich, Nottingham, Plymouth
- Életkor
- 18 év and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - 3. fázisTaking peopleA Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Where
- Aberdeen, Birmingham, Bournemouth, London, Southampton
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06846671 · EU 2024-518893-15-00 - 3. fázisTaking peopleA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Where
- Brighton, Canterbury, Norwich, Oxford, Roundhay, Salisbury
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00 - 3. fázisTaking peopleA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Where
- Birmingham, Bournemouth, Leeds, London, Norwich
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07277231 · EU 2025-524366-21-00 - 4. fázisTaking peopleAcalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
- Where
- Bournemouth, Oxford, Plymouth, Romford, Stockton, Sutton Coldfield
- Életkor
- 18 év to 130 év
- People
- 60 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06651970 - No phaseNot yet taking people in Egyesült KirályságvariaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway
- Where
- Wolverhampton
- People
- 130
- Run by
- The Royal Wolverhampton Hospitals NHS Trust
See details and how to joinNCT07463976 - No phaseTaking peopleObservational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
- Where
- Aylesbury, Bath, Birmingham, Bournemouth, Cardiff, Cornwall, Dartford, Derby, Doncaster, Dorset, Eastbourne, Hull, Leicester, Lincoln, Liverpool, London, Middlesbrough, Mid Yorkshire, Newcastle, North Shields, Norwich, Nottingham, Oxford, Plymouth, Southampton, Stockton-on-Tees, Stoke-on-Trent, Wigan
- Életkor
- 18 év to 130 év
- People
- 287
- Run by
- AstraZeneca
See details and how to joinNCT05557695 - 3. fázisTaking peopleA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Where
- Bristol, Leicester, London, Swansea
- Életkor
- 18 év and over
- People
- 737 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00 - 1. fázisTaking peopleDose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
- Where
- Leeds, Plymouth
- Életkor
- 18 év and over
- People
- 85 worldwide
- Run by
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT06980116 · EU 2024-516869-36-00 - 1. fázisTaking peopleA Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Where
- Glasgow, Leeds, Liverpool, London, Manchester, Oxford, Plymouth, Southampton, Sutton
- Életkor
- 18 év and over
- People
- 572 worldwide
- Run by
- Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00